Glioblastoma Multiforme Market Set for Strong Growth to USD 6.81 Billion by 2033, Led by North America's 41% Global Market Share | DataM Intelligence

The Global Glioblastoma Multiforme Market reached USD 2.92 billion in 2024 and is expected to reach USD 6.81 billion by 2033, growing at a strong CAGR of 9.6% during the forecast period 2025-2033.

Market growth is driven by the rising incidence of glioblastoma, increasing investments in oncology research, and advancements in targeted therapies, immunotherapy, and combination treatment approaches. Additionally, growing awareness of early diagnosis, expansion of clinical trials, and improvements in drug delivery technologies such as blood-brain barrier penetration are further supporting market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/glioblastoma-multiforme-market?ram

United States: Key Industry Developments
✅ December 2025: Alpha Tau successfully treated the first patient in its U.S. trial for recurrent glioblastoma at James Cancer Hospital using Alpha DaRT technology, supported by FDA Breakthrough Device Designation.​

✅ November 2025: FDA granted orphan drug designation to tinostamustine for malignant gliomas including glioblastoma, with early Phase 1 results showing tolerable safety and clinical activity in unmethylated-MGMT GBM.​

✅ October 2025: FDA cleared a novel phase 1b/2a combination trial for recurrent glioblastoma using STAR-001, building on ongoing monotherapy studies to address unmet needs in brain cancer treatment.​

Asia Pacific / Japan: Key Industry Developments
✅ June 2025: SymBio Pharmaceuticals completed first patient enrollment in Japan for its global Phase Ib/II trial of BCV targeting malignant lymphoma, with expansion plans across Asia-Pacific sites.​

✅ April 2025: Japan approved the world's first oncolytic virus therapy, Teserpaturev (G47Δ), for malignant brain tumors including glioblastoma, offering improved survival rates over standard treatments.​

✅ Japan 2025: The glioblastoma multiforme treatment market expanded through advanced oncology integration, with rising adoption of temozolomide, TTF therapy, and precision medicine programs.​

Key Merges and Acquisitions(2025):
✅ Leading biopharma firms enhanced their glioblastoma multiforme portfolios through strategic acquisitions of innovative therapeutics platforms, accelerating clinical pipelines and therapeutic advancements.​

✅ Major oncology players expanded treatment capabilities via mergers targeting novel drug delivery systems and precision medicine assets in glioblastoma multiforme.​

✅ Pharmaceutical giants pursued collaborations and buyouts of biotech entities specializing in glioblastoma multiforme immunotherapies to strengthen market positions and R&D synergies.

Market Segmentation Analysis:
-By Product Type: Surgery Leads with Dominant Share
Surgery holds 33% market share in 2024, serving as the primary initial treatment for tumor resection to maximize survival rates and enable subsequent therapies.​
Radiation Therapy follows as the fastest-growing segment, leveraging advanced techniques like stereotactic radiosurgery for precise targeting post-surgery.​
Chemotherapy, Immunotherapy, and Others (including targeted therapy and tumor treating fields) comprise the balance, with immunotherapy gaining traction for personalized immune responses.​

-By Drugs: Temozolomide Commands the Market
Temozolomide (TMZ) dominates the drug class segment due to its standard-of-care status in combination regimens like Stupp protocol for newly diagnosed cases.​
Bevacizumab captures significant share for recurrent GBM via anti-angiogenesis, while Lomustine and Others (e.g., carboplatin, cisplatin) support salvage therapies.​
These drugs drive ~9-12% CAGR overall, fueled by ongoing trials enhancing efficacy.​

-By Distribution Channel: Hospitals Overwhelm with Volume
Hospitals lead with 48% market share, providing comprehensive care infrastructure for complex surgeries, radiation, and multidisciplinary teams.​
Specialty Clinics hold 30% as the second-largest, excelling in outpatient chemotherapy, immunotherapy infusions, and follow-ups.​
Others (e.g., ambulatory centers) fill the remainder, focusing on supportive care amid rising decentralized models.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=glioblastoma-multiforme-market?ram (Purchase 2 or more Reports and get 50% Discount)

Why is the Glioblastoma Multiforme Market Growing?
The Glioblastoma Multiforme (GBM) market in 2025 is expanding rapidly due to rising incidence rates and breakthroughs in oncology treatments.​

-Rising Incidence and Early Diagnosis: Higher global rates of brain tumors, coupled with improved diagnostic imaging like advanced MRI, enable earlier detection and more aggressive interventions.​

-Innovative Therapies: Emergence of immunotherapies, targeted drugs, and tumor-treating fields (TTFields) is reshaping treatment options and extending patient survival.​

-Personalized Medicine Advances: Tailored approaches using genetic profiling are gaining traction, especially in North America, boosting efficacy over traditional chemotherapy.​

-Regional Momentum: Asia-Pacific leads fastest growth through increased healthcare investments, clinical trials, and government support for cancer care infrastructure.​

Regional Insights:
-North America leads the Glioblastoma Multiforme market with the highest regional share, accounting for approximately 41% in recent years, driven by advanced healthcare infrastructure, high R&D investments, and early adoption of therapies like tumor treating fields.​

-Europe follows as the second-largest market, benefiting from strong regulatory frameworks and ongoing clinical trials, though specific share figures hover around 28% based on global breakdowns from multiple reports.​

-Asia Pacific ranks third in market share, estimated at 18%, with rapid growth fueled by rising healthcare access, increasing incidence rates, and expanding pharma manufacturing, positioning it as the fastest-growing region.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/glioblastoma-multiforme-market?ram

Key Players:
Genentech (Roche) | Pfizer | Amgen | Merck & Co. | VBI Vaccines | Starlight Therapeutics

Key Highlights (Top 5 Key Players) for Glioblastoma Multiforme Market:
-Genentech (Roche) develops bevacizumab (Avastin), an anti-VEGF monoclonal antibody approved for recurrent glioblastoma to inhibit tumor angiogenesis and extend progression-free survival.

-Pfizer advances small molecule inhibitors and immunotherapies targeting GBM pathways like EGFR and PD-1, including clinical trials combining chemotherapy with novel agents for newly diagnosed patients.

-Amgen focuses on biologics and targeted therapies such as EGFR inhibitors and bispecific antibodies to enhance immune response against GBM tumor cells.

-Merck & Co. leads with pembrolizumab (Keytruda), a PD-1 inhibitor in combination trials with radiation and temozolomide to overcome GBM's immunosuppressive microenvironment.

-VBI Vaccines develops synthetic peptide-based immunotherapies like VBI-1901, stimulating T-cell responses against GBM-specific antigens in Phase I/II trials for recurrent disease.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.